Cefixime vs Ciprofloxacin for Acute Uncomplicated Cystitis: Clinico-Economic Study | CMAC

Cefixime vs Ciprofloxacin for Acute Uncomplicated Cystitis: Clinico-Economic Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(1):59-66

​ Galkin V.V., Dovgan E.V., Kozlov S.N., Rafalskiy V.V.
acute cystitis cefixime ciprofloxacin pharmacoeconomics
Section
Pharmacoeconomics
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(1):59-66

Objective.

To evaluate clinico-economical effectiveness of short course of cefixime and ciprofloxacin in women with acute uncomplicated cystitis.

Materials and Methods.

A prospective randomized clinico-economic study of effectiveness of cefixime and ciprofloxacin in 104 patients with acute uncomplicated cystitis.

Results.

At visit 2 (day 8) microbiological cure rates were detected in 95.9%, 55.6% and 71.4% of patients from Group 1 (cefixime), Group 2-a (ciprofloxacin 250 mg BID) and Group 2-b (ciprofloxacin 500 mg BID), respectively. The direct costs were 2935.6 RUR (ciprofloxacin 500 mg BID), 3096.8 RUR (cefixime 400 mg once a day) and 4048 RUR (ciprofloxacin 250 mg BID). The «costeffectiveness» rate for each treatment regimen (RUR / 1% eradication), was 7280.6, 4111.5 and 3229.2 for ciprofloxacin (250 mg), ciprofloxacin (500 mg) and cefixime (400 mg), respectively.

Conclusions.

Cefixime (400 mg once a day 5 days) is more microbiologicaly effective compare to ciprofloxacin (250–500 mg BID 5 days) in patients with acute uncomplicated cystitis. Short course of cefixime is more cost-effective than short course of ciprofloxacin (250–500 mg BID) in patients with acute uncomplicated cystitis.

  • 1. Dielubanza E.J., Schaeffer A.J. Urinary tract infections in women. Med Clin North Am 2011; 95:27-41.
  • 2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113:5-13.
  • 3. Лоран О.Б. Эпидемиологические аспекты инфекций мочевыводящих путей. Материалы симпозиума «Инфекции мочевыводящих путей у амбулаторных больных». Москва, 1999: 5-8.
  • 4. Hooton T.M., Stamm W.E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11:551-81.
  • 5. Рафальский В.В., Белокрысенко С.С., Малев И.В. и др. Чувствительность возбудителей инфекций мочевыводящих путей, выделенных в Российской Федерации, к пероральному цефалоспорину III поколения цефиксиму. Лечащий врач 2008; 8:27-29.
  • 6. Белоусов Ю.Б., Шмат С.С., Селевина Т.Г., Ефременкова О.В. Фармакоэкономика лечения инфекций нижних дыхательных путей в амбулаторных условиях. Пульмонология 2000; 3:77-9.
  • 7. Goldman M.P., Nair R. Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics? Cleve Clin J Med 2007; 74 Suppl 4:S38-47.
  • 8. Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infections. Int J Antimicrob Agents 1999; 11:247-51.
  • 9. Kahan N.R., Kahan E., Waitman D.A., Chinitz D.P. Economic evaluation of an updated guideline for the empiric treatment of uncomplicated urinary tract infection in women. Isr Med Assoc J 2004; 6:58-91.
  • 10. Barry H.C., Ebell M.H., Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract 1997; 44:49-60.
  • 11. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» ОСТ 91500.14.0001- 2002.
  • 12. Vorobieva V., Semenova N., Bjorg C. Haldorsen, Bettina Aasnaes, Umaer Naseer, Gunnar Simonsen, Arnfinn Sundsfjord. Clinical urinary tract isolates of Enterobacteriaceae in the Arkhangelsk region, Russia: Antimicrobial resistance profiles and characterization of ESBL-strains. 17th ECCMID/ 25th ICC March 31- April 3, 2007, Munich, Germany 2007.
  • 13. Галкин В.В., Малев И.В., Довгань Е.В., Козлов С.Н., Рафальский В.В. Эффективность и безопасность цефиксима и ципрофлоксацина при остром цистите (Многоцентровое рандомизированное исследование). Урология 2011; 1:13-6.
  • 14. Iravani A., Richard G., Johnson D., Bryant A. A doubleblinding, multicenter comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patient. American Journal of Medicine 1988; 85:17-25.
  • 15. Levenstein J., Summerfield P.J., Fourie S., Brink G., Michaelides B., Murray E., Naidoo N. Comparison of cefixime and co-trimoxazole in acute uncomplicated urinary tract infection. A double-blind general practice study. South African medical journal 1986; 70:455-60.
  • 16. Ceran N., Mert D., Kocdogan F.Y., Erdem I., Adalati R., Ozyurek S., Goktas P. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother 2010; 16(6):424-30.
  • 17. Новоселова Е. Дженерики без границ, 2008. Доступно на сайте: URL http://www.biorf.ru/catalog.aspx?cat_id=394&d_no=1593
  • 18. Tally F., Desjardins R., McCarthy E., Cartwright K. Safety profile of cefixime. Pediatric Infectious Disease 1987; 6:976-80.
  • 19. Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother. 1986; 18 (Suppl D):187-93.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared